Podcast
Skin in the Game
Hosted by Diego Ruiz Dasilva, MD, FAAD & Graham Litchman, DO, MS, FAAD · EN
We read the research so you don’t have to.
As a Dermatology podcast, we do things a little differently: we start every episode with immediately actionable clinical pearls—right up front. No fluff, no waiting.
So even if you’ve got five minutes between patients, you’ll still walk away with something you can actually use in clinic that day.
And if you want more—the “why,” the nuance, the deeper dive into the data—just keep listening.
Think of it as dermatology on your terms: quick when you need it, more when you want it.
We’re not here to just read papers and repeat the results.
We’re here to take the data, the ideas, the nuance—and make them more approachable, more usable…and ultimately more relevant to what actually happens in clinic.
5episodes
Episodes
Newest firstAll episodes
From Black Box to Bargain Price: The Tofacitinib Comeback?
5d ago00:16:45Tap to summarizeTofacitinib was the first oral JAK inhibitor to transform the treatment of inflammatory disease but after the ORAL Surveillance trial, its boxed warning reshaped how many clinicians viewed the entire class.Now, everything is changing again.With generic tofacitinib becoming dramatically less expensive, clinicians are asking whether it’s time to take another look. In this episode of Skin in the Game, Drs. Diego Ruiz Dasilva and Graham Litchman unpack the history of tofacitinib, what the boxed warning actually means, how to interpret the available safety data, and where the drug may still have an important role in dermatology.Whether you’re excited about the affordability of generic JAK inhibitors or remain cautious because of the boxed warning, this episode explores the evidence behind the headlines.Skin in the Game delivers high-yield dermatology quick hits for busy clinicians.Hosted by: • Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV • Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VAWe read the research so you don’t have to.For show notes and more information please visit our website at https://skininthegamepodcast.buzzsprout.com/Disclaimer: This podcast is intended for educational purposes only and does not constitute medical advice. Views expressed are those of the hosts and do not necessarily reflect those of their employers or affiliated organizations.
Transcribe →Which Psoriasis Therapy Comes Out on Top? Breaking Down the Latest Network Meta-Analysis
2w ago00:14:33Tap to summarizeWith more treatment options than ever, choosing the right therapy for psoriasis isn’t always straightforward. In this episode of Skin in the Game, we break down the latest JAMA Dermatology meta-analysis comparing systemic treatments for plaque psoriasis. We discuss which therapies rise to the top, the strengths and limitations of network meta-analyses, and what these findings mean for real-world clinical practice.Join us for a practical, evidence-based discussion with actionable takeaways for busy clinicians.Skin in the Game delivers high-yield dermatology quick hits for busy clinicians.Hosted by: • Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV • Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VAWe read the research so you don’t have to.For show notes and more information please visit our website at https://skininthegamepodcast.buzzsprout.com/Disclaimer: This podcast is intended for educational purposes only and does not constitute medical advice. Views expressed are those of the hosts and do not necessarily reflect those of their employers or affiliated organizations.
Transcribe →The IDENTITY Trial - Can Precision Medicine Transform Atopic Dermatitis Care?
3w ago00:15:14Tap to summarizeFor decades, systemic therapy selection in atopic dermatitis has largely relied on clinical judgment and trial-and-error. The prospective IDENTITY study by Silverberg and colleagues challenges that paradigm.In this episode of Skin in the Game, we unpack the landmark JAAD study evaluating a 487-gene expression profile designed to identify the dominant inflammatory pathway in individual patients and guide systemic treatment selection. We discuss how the test works, review the study design and key efficacy outcomes, explore its strengths and limitations, and debate whether molecular phenotyping is ready for everyday clinical practice.Most importantly, we discuss what this means for real-world dermatologists: Which patients might benefit? How could this change treatment sequencing? And are we entering the era of precision medicine for atopic dermatitis?Join us as we separate the hype from the evidence and discuss whether IDENTITY represents the future of personalized AD care. Skin in the Game delivers high-yield dermatology quick hits for busy clinicians.Hosted by: • Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV • Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VAWe read the research so you don’t have to.For show notes and more information please visit our website at https://skininthegamepodcast.buzzsprout.com/Disclaimer: This podcast is intended for educational purposes only and does not constitute medical advice. Views expressed are those of the hosts and do not necessarily reflect those of their employers or affiliated organizations.
Transcribe →Finasteride, Dutasteride & Sexual Side Effects - What Does the Evidence Really Show?
4w ago00:11:34Tap to summarizeFew topics in dermatology spark more debate than the sexual side effects of oral finasteride. In this episode of Skin in the Game, we break down the latest evidence comparing finasteride and dutasteride, including a new pharmacovigilance analysis, and discuss what these data can—and can’t—tell us about real-world risk.We explore the strengths and limitations of adverse event databases, the role of reporting bias and the nocebo effect, and how to counsel patients using the best available evidence. Finally, we discuss whether dutasteride truly differs from finasteride and what these findings mean for everyday clinical practice.Join us as we separate myth from evidence and provide practical, evidence-based takeaways for clinicians treating patients with androgenetic alopecia.Skin in the Game delivers high-yield dermatology quick hits for busy clinicians.Hosted by: • Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV • Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VAWe read the research so you don’t have to.For show notes and more information please visit our website at https://skininthegamepodcast.buzzsprout.com/Disclaimer: This podcast is intended for educational purposes only and does not constitute medical advice. Views expressed are those of the hosts and do not necessarily reflect those of their employers or affiliated organizations.
Transcribe →Getting Some Skin in the Game
Jul 600:17:22Tap to summarizeWelcome to Skin in the Game, a dermatology podcast delivering high-yield clinical pearls for busy clinicians. Hosted by dermatologists Graham Litchman and Diego Ruiz Dasilva: we break down the latest research and translate it into practical insights you can use immediately in clinic.In our inaugural episode, we explain the philosophy behind the podcast and discuss the paper “Assessing Risk Amid Uncertainty Inside and Outside the Dermatology Clinic” by Vanderweil et al. Together, we explore how physicians perceive risk, why rare adverse events often loom larger than common disease burdens, and how framing uncertainty can influence patient care.Sponsored by ReachRx: Instant answers to clinical questions. Save time, stay updated, and ensure accuracy with the search engine built for medicine—free for clinicians.Skin in the Game delivers high-yield dermatology quick hits for busy clinicians.Hosted by: • Graham Litchman, DO, MS — Vivida Dermatology, Las Vegas, NV • Diego Ruiz Dasilva, MD — Forefront Dermatology, Virginia Beach, VAWe read the research so you don’t have to.For show notes and more information please visit our website at https://skininthegamepodcast.buzzsprout.com/Disclaimer: This podcast is intended for educational purposes only and does not constitute medical advice. Views expressed are those of the hosts and do not necessarily reflect those of their employers or affiliated organizations.
Transcribe →